Find Clinical Trial

A Multicentre, Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)


← Back
Study Phase

Phase 2

Therapeutic Area

Cancers

IndicationAcute Lymphoblastic Leukemia
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active substance/
Medical device

PEGASPARGASE,
S095014

Active Substance CodeS095014
Protocol CodeCL2-95014-003
NCT CodeNCT04956666


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2021 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility